Syschem (India) (531173)

Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

When I look at Syschem, I see fast growth, but I must apply caution. A pharma business reporting sales up 82% and profit up 734% gets attention, but Graham taught me to value facts, not stories. The latest quarter shows sales of ₹142 Cr and net profit of ₹4 Cr, implying a thin net margin of roughly 2.8%. At a market cap of ₹165 Cr, today's earnings justify the price only if this growth continues. With a P/E of 25.78 and a P/B of 3.09, the market is already paying for good news. Book value of ₹13.35 gives only a modest cushion. ROE of 14.53% is respectable, but ROCE of 1.47% is alarming. That gap suggests operating returns are weak and the apparent equity return may be driven by leverage or one-off items. Without debt-to-equity or promoter holding data, I cannot assess balance sheet risk or whether management is aligned with minority shareholders. The Piotroski F-Score of 7/9 is decent, and a PEG of 0.06 looks inexpensive, but a PEG built on a 734% profit spike is meaningless if that growth is cyclical or non-recurring. The stock pays no dividend, so the investor depends entirely on price appreciation. It now trades near its 52-week low of ₹40.50, showing that momentum has reversed despite the headline numbers. In Buffett style, I prefer wonderful businesses at fair prices, and here I do not yet know if Syschem is wonderful. Low ROCE, thin margins, and unclear capital structure are serious red flags. I would wait for consistent margins, better return on capital, and cleaner financials before committing capital.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer